Production (Stage)
E
Cingulate Inc. CING
$4.20 -$0.20-4.55% NASDAQ
Recommendation
Prev Close
$4.20
Volume
66,890
Avg Vol (90D)
132,332
Market Cap
$17.83M
Dividend & Yield
--
52-Week Range
$1.80 - $20.83
P/E (TTM)
--
EPS (TTM)
-$10.21
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Cingulate Inc. (NASDAQ:CING) Sees Large Drop in Short Interest
6/2/2025 - Ticker Report
Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer
5/27/2025 - PR Newswire
Ascendiant Sticks to Their Buy Rating for Cingulate Inc (CING)
5/27/2025 - TipRanks Financial Blog
Cingulate Retail Buzz Surges As ADHD Drug Shows Phase 3 Pediatric Efficacy
5/21/2025 - Stocktwits News Feed
Efficacy Results Announced from Cingulate's Phase 3 Pediatric Study of CTx-1301 ...
5/20/2025 - GuruFocus
Cingulate (CING) Reveals Promising Phase 3 Results for ADHD Treatment CING Stock News
5/20/2025 - GuruFocus
Cingulate announces efficacy results from Phase 3 study of CTx-1301
5/20/2025 - The Fly
Efficacy Results Announced from Cingulate's Phase 3 Pediatric Study of CTx-1301 ...
5/20/2025 - GuruFocus
Efficacy Results Announced from Cingulate's Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD
5/20/2025 - Globe Newswire
Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), Waters (WAT) and Cingulate Inc (CING)
5/19/2025 - TipRanks Financial Blog
Cingulate price target lowered to $11 from $12 at Roth Capital
5/19/2025 - TipRanks Financial Blog
Cingulate price target lowered by $1 at Roth Capital, here's why
5/19/2025 - The Fly
Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug
5/15/2025 - Stocktwits News Feed
Cingulate (CING) Prepares for NDA Submission for ADHD Treatment CING Stock News
5/14/2025 - GuruFocus
Cingulate receives formal pre-NDA meeting minutes from FDA for CTx-1301
5/14/2025 - The Fly
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset ...
5/14/2025 - GuruFocus
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301
5/14/2025 - Globe Newswire
Cingulate reports Q1 results
5/9/2025 - SeekingAlpha.com: All News
Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of ...
5/8/2025 - GuruFocus
Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of ...
5/8/2025 - GuruFocus
Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets
5/8/2025 - Globe Newswire
Cingulate Inc. (NASDAQ:CING) Sees Significant Growth in Short Interest
5/5/2025 - Ticker Report
Cingulate announces results from high-dose fed/fast study of CTx-1301
4/29/2025 - The Fly
Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead ...
4/29/2025 - GuruFocus
Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD
4/29/2025 - Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$15.75M
EBIT (TTM)
-$16.40M
Net Income (TTM)
-$16.38M
Balance Sheet
Total Assets (Q)
$12.47M
Total Debt (Q)
$5.08M
Total Liabilities (Q)
$6.54M
Book Value Per Share (Q)
$1.55
Cash Flow
Cash from Operations (TTM)
-$14.31M
Cash from Investing (TTM)
-$130.30K
Cash from Financing (TTM)
$22.85M
Net Change in Cash (TTM)
$8.41M
Filings
Filing Date
Thursday, May 8, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 11 and 15 (est)
Price History
Loading...
Beta
5.65
7-Day Total Return
-1.06%
30-Day Total Return
-2.78%
60-Day Total Return
2.69%
90-Day Total Return
-11.21%
Year to Date Total Return
-17.65%
1-Year Total Return
-47.06%
2-Year Total Return
-98.20%
3-Year Total Return
-98.57%
5-Year Total Return
--
52-week Low
Aug 14, 2024 - $1.80
52-week High
Aug 16, 2024 - $20.83
Valuation
Market Cap
$17.83M - Nano Cap
Enterprise Value
$13.39M
Price/Sales (TTM)
--
Price/Book (Q)
2.71
Dividends and Shares
Shares Outstanding
3.65M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.cingulate.com
Phone Number
913 942 2300
Address
1901 West 47th Place
Kansas City, KS 66205
Country
United States
Year Founded
2012
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company... more
NASDAQ 06/13/2025 3:59PM Eastern Quotes delayed